A recent study finds that the N6-methyladenosine (m6A) modifier METTL3 regulates proliferation and differentiation in myeloid cells and acute myeloid leukemia (AML).
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kwaja, A. et al. Nat. Rev. Dis. Primers 2, 16010 (2016).
Batista, P.J. et al. Cell Stem Cell 15, 707–719 (2014).
Geula, S. et al. Science 347, 1002–1006 (2015).
Li, H.-B. et al. Nature 548, 338–342 (2017).
Vu, L.P. et al. Nat. Med. 23, 1369–1376 (2017).
Batista, P.J. Genomics Proteomics Bioinformatics 15, 154–163 (2017).
Keene, J.D. Nat. Rev. Genet. 8, 533–543 (2007).
Edupuganti, R.R. et al. Nat. Struct. Mol. Biol. 24, 870–878 (2017).
Liu, N. et al. Nature 518, 560–564 (2015).
Spitale, R.C. et al. Nature 519, 486–490 (2015).
Cui, Q. et al. Cell Rep. 18, 2622–2634 (2017).
Zhang, S. et al. Cancer Cell 31, 591–606 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Schmiechen, A., Batista, P. An epitranscriptomic vulnerability in myeloid malignancies. Nat Med 23, 1252–1254 (2017). https://doi.org/10.1038/nm.4435
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.4435